Bayer: 5 key drugs to have combined peak sales of 5.5 billion euro
LEVERKUSEN, Germany (Reuters) - Bayer said its five most promising new drugs have an annual peak sales potential of more than 5.5 billion euros ($7 billion).
The sales forecast comprises anti-clotting pill Xarelto, ophthalmic drug Eylea, also calle VEGF Trap-Eye, anti-cancer products Alpharadin and Stivarga, as well as lung treatment riociguat.
Last year, Bayer said four of the drugs, excluding riociguat, would have a peak sales potential of more than 5 billion euros.
(Reporting by Frank Siebelt; Writing by Ludwig Burger)
- Tweet this
- Share this
- Digg this
New York and New Jersey will automatically quarantine medical workers returning from Ebola-hit West African countries and the U.S. government is considering the same step after a doctor who treated patients in Guinea came back infected, officials said. Full Article | Slideshow